AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Gaining IL-13 Antibody Zumilokibart

AbbVie announced on June 22, 2026, a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion.¹ The deal provides AbbVie with global rights to zumilokibart and Apogee's broader pipeline of half-life extension (HLE) biologics targeting type 2 inflammatory diseases.

The acquisition arrives as AbbVie continues to diversify its immunology portfolio ahead of ongoing Skyrizi and Rinvoq lifecycle management. Robert A. Michael, Chairman and CEO of AbbVie, emphasized the strategic fit: "With our deep scientific expertise and proven capabilities, we are uniquely positioned to rapidly advance these programs."¹

The transaction is expected to close in the second half of 2026.

What is zumilokibart, and what is its mechanism of action?

Zumilokibart (APG777) is a subcutaneous, HLE monoclonal antibody targeting interleukin-13 (IL-13), a cytokine central to the pathogenesis of atopic dermatitis (AD) and related type 2 inflammatory diseases. IL-13 drives epidermal barrier dysfunction, Th2-skewed immune activation, and the chronic itch-scratch cycle that defines moderate-to-severe AD.¹ By selectively blocking IL-13 signaling, zumilokibart is designed to suppress these downstream inflammatory cascades while offering a subcutaneous formulation optimized for extended dosing intervals.

Apogee engineered zumilokibart using an HLE platform, allowing infrequent dosing that may differentiate it in a market currently anchored by dupilumab (brand name Dupixent), a dual IL-4/IL-13 blocker that generated approximately $17.8 billion in global sales in 2025.⁴ Whether selective IL-13 inhibition delivers comparable or superior efficacy to dual blockade remains an open clinical question that the ongoing phase 3 program is designed to answer.

What did the phase 2 data show?

In phase 2 trials, zumilokibart demonstrated rapid and durable improvements in Eczema Area and Severity Index scores in patients with moderate-to-severe AD, with an acceptable safety profile consistent with the IL-13 mechanistic class.² BioPharm International previously reported on the phase 2 readout, noting that response rates were competitive with approved biologics in the space and that the HLE design supported the extended-interval dosing hypothesis.³

The molecule is also being evaluated in asthma and eosinophilic esophagitis, broadening the potential addressable population across the type 2 inflammatory disease spectrum.

How does zumilokibart fit into the broader HLE antibody landscape?

The HLE antibody engineering approach — designed to extend the serum half-life of monoclonal antibodies and reduce dosing frequency — has attracted significant commercial and scientific interest across inflammatory and other indications. BioPharm International recently covered a licensing deal between Bionyra and TrueLab centered on a TL1A-targeting HLE antibody for inflammatory bowel disease, reflecting growing industry investment in this class of molecules.⁵

For AbbVie, zumilokibart represents a high-conviction bet on differentiated IL-13 biology at phase 3 readiness — a de-risked profile that justifies the premium acquisition price in a competitive immunology market.

References

1. AbbVie to Acquire Apogee Therapeutics. (2026 Jun 22). AbbVie and Apogee Therapeutics. https://news.abbvie.com/2026-06-22-AbbVie-to-Acquire-Apogee-Therapeutics,-Deepening-Immunology-Portfolio
2. Guttman-Yassky E, et al. (2017 Sep). Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. https://pubmed.ncbi.nlm.nih.gov/28895955/
3. Schoenthaler, E. (2026 May 27). Apogee’s Zumilokibart Advances Toward Phase 3 After Positive Phase 2 Atopic Dermatitis Results. BioPharm International. https://www.biopharminternational.com/view/apogee-s-zumilokibart-advances-toward-phase-3-after-positive-phase-2-atopic-dermatitis-results
4. 2025: strong sales and EPS growth. Continued profitable growth expected in 2026. (2026 Jan 29). Sanofi. https://www.sanofi.com/en/media-room/press-releases/2026/2026-01-29-06-30-00-3228191
5. Schoenthaler, E. (2026 Jun 22). Bionyra Pharma Launches with $165M and Two TL1A Biologics Licensed From TrueLab, Entering Crowded IBD Race BioPharm International. https://www.biopharminternational.com/view/bionyra-pharma-launches-with-165m-and-two-tl1a-biologics-licensed-from-truelab-entering-crowded-ibd-race